StockTipsArenaBeta

BUY Wockhardt Limited — Gaurav Sharma, Globe Capital Market

BUYWockhardt Limited
Wockhardt share price target & all analyst calls

byGaurav Sharma, Globe Capital MarketHorizon: NA (inferred Swing (≤2wk))11 Jun 2026via CNBC Awaaz.

Entry₹1,932Stated
Target₹2,100
Total upside +8.70% (call closed)
Stop loss₹1,860-3.73% risk
Exit₹2,10018 Jun 2026, 9:50 am
Target hit+8.70%0.00%upside left
Follow Gaurav Sharma for new calls(27% target hit, 98 closed calls)Get alertsWatch WOCKPHARMA for new buy/sell callsGet alertsSee 108 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 22 Oct, 8:49 am IST
1 supporting0 opposing
Supports the BUY call (1)

Wockhardt Limited received U.S. FDA approval for ZAYNICH (cefepime and zidebactam), a novel intravenous antibiotic for treating complicated urinary tract infections in adults.

NSE · Press Release·30 May · 3w ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Wockhardt

All analyst calls on Wockhardt

More from Gaurav Sharma, Globe Capital Market

Every call and its outcome